SHERIDAN, WYOMING – November 08, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline. The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development. Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues. "We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.

SHERIDAN, WYOMING – November 07, 2024 – Abbott, a global healthcare leader, is proud to announce the formation of Team Abbott, a worldwide community of runners united by their passion for health and fitness. This initiative underscores Abbott's commitment to helping people live their best lives through the power of good health. The inspiration behind Team Abbott stems from the recognition that marathons, while individual races, are ultimately a team sport. "Ask anyone who has run one and they’ll tell you: Marathons are a team sport," says an Abbott spokesperson. "Literally speaking, no, marathons can’t be relayed by a team of athletes, nor are they won by team organizations. But the process of training to run 26.2 miles, and attaining the health needed to do so, is a team effort."

SHERIDAN, WYOMING – November 7, 2024 – In an era marked by growing health concerns and disparities, Tanzania is taking proactive strides to bolster its healthcare system. Through strategic investment in medical education and capacity building, the nation is fostering a skilled healthcare workforce to address its unique challenges and improve the well-being of its citizens. A collaborative endeavor between the Tanzanian Ministry of Health, Siemens Healthineers, and Muhimbili National Hospital (MNH) has yielded a specialized training program for medical engineers and radiographers. Over the past two years, this initiative has empowered more than 100 healthcare professionals with advanced skills in operating state-of-the-art imaging equipment.

SHERIDAN, WYOMING – November 07, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game. The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.

Sydney Marathon Joins Abbott World Marathon Majors as 7th Race SHERIDAN, WYOMING – November 7, 2024 – The world of marathon running has expanded with the addition of the TCS Sydney Marathon presented by Asics to the Abbott World Marathon Majors (AWMM). Starting in 2025, Sydney will join the prestigious ranks of Tokyo, Boston, London, Berlin, Chicago, and New York in hosting one of the world's most renowned marathons.

SHERIDAN, WYOMING – November 07, 2024 – Abbott (NYSE: ABT) today announced significant strides in its pulsed field ablation (PFA) solutions within the electrophysiology field. The company has achieved key milestones, including the early completion of enrollment in the VOLT-AF IDE Study for the Volt™ PFA System and the initiation of the FOCALFLEX trial to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), designed for treating paroxysmal atrial fibrillation. These advancements underscore Abbott's commitment to providing innovative solutions for abnormal heart rhythms like atrial fibrillation (AFib).

SHERIDAN, WYOMING – November 07, 2024 – GE HealthCare, a leading global medical technology and diagnostics company, is poised to announce its latest quarterly earnings before the market opens on Wednesday. Financial analysts are predicting an increase in both revenue and profits compared to the same period last year, signaling continued resilience amidst a challenging global economic landscape.

SHERIDAN, WYOMING – November 07, 2024-Roche (SIX: RO, ROG; OTCQX: RHHBY) has opened its new Pharma Research and Early Development Center (pRED) at its global headquarters in Basel. The center has 1,800 laboratory and office workplaces, bringing together researchers from different disciplines, explains Roche in a statement. The center’s inauguration was attended by Federal Councillor Guy Parmelin, Head of the Federal Department of Economic Affairs, Education and Research.

SHERIDAN, WYOMING – November 07, 2024 – Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present a robust body of data at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. With more than 40 abstracts spanning nine blood disorders, Roche's presence at ASH underscores its unwavering dedication to improving outcomes for individuals battling lymphoma.